Stability testing remains a cornerstone of pharmaceutical development, providing critical data to ensure that drugs are safe, effective, and consistent throughout their shelf life. The International Council for Harmonisation (ICH) recently released its draft Q1 guideline, consolidating multiple stability guidances into a single, comprehensive document. While the industry has welcomed this effort to streamline and modernize regulatory expectations, stakeholders are also raising important questions about the guideline’s scope and how stability studies should be timed.
Support for Consolidation
Organizations such as the International Society for Pharmaceutical Engineering (ISPE) and Biocom California applauded the consolidation of five separate stability guidelines into one. They noted that the draft guidance extends its scope to cover product categories that were previously not included, such as advanced therapy medicinal products (ATMPs), vaccines, and complex biologics. For these groups, the new guideline offers greater clarity and consistency, particularly for companies working across diverse product platforms.
Concerns About Shelf-Life Requirements
Despite the positive feedback, concerns remain about the level of detail provided on stability requirements for biologics. The Association for Accessible Medicines (AAM) called for clearer instructions on when sponsors must submit full-duration shelf-life data and when six months of stability data may be sufficient. AAM emphasized that without more specific criteria, manufacturers are left uncertain about what regulators will require, which could create delays in product approvals. This ambiguity is particularly challenging for generic drug developers, who often face tight development timelines and budgets.
Calls to Expand the Guideline’s Scope
Some groups argued that the draft guideline does not go far enough in defining which products fall under its recommendations. The American Association of Pharmaceutical Scientists (AAPS) urged the inclusion of botanicals, live bacterial therapies, and bacteriophage products—categories that are becoming increasingly relevant in today’s drug development pipeline. Similarly, the Parenteral Drug Association (PDA) requested explicit coverage of radiopharmaceuticals, pointing out that while their shelf life is shorter, the same scientific principles of stability still apply. PDA also highlighted the need for more detailed guidance on ATMPs, which pose unique stability challenges due to their susceptibility to degradation pathways not seen in traditional small molecules.
Balancing Science and Regulatory Boundaries
While the new guideline incorporates modern scientific approaches such as stability modeling, matrixing, and bracketing, some stakeholders believe it goes beyond its intended scope. ISPE suggested removing references to Good Manufacturing Practice (GMP) requirements, arguing that these are more appropriately addressed in separate GMP guidelines. Mixing technical stability testing with GMP expectations, they cautioned, could create confusion about regulatory boundaries and compliance obligations.
The Path Forward
The feedback on the draft Q1 guideline underscores the complexity of developing a harmonized framework that addresses the needs of a broad and evolving industry. Advanced therapies, biologics, and novel drug platforms each present distinct stability challenges that cannot always be addressed with one-size-fits-all rules. At the same time, regulators must balance scientific rigor with clarity and flexibility to avoid delaying patient access to essential medicines.
As the consultation process continues, further refinements to the Q1 guideline are expected. The final version will likely play a pivotal role in shaping how pharmaceutical companies worldwide design and implement their stability programs. Clearer expectations on timing, scope, and product categories will help streamline development while maintaining the high standards of safety and efficacy that patients depend on.
For companies navigating these changes, expert guidance is essential. Firms like EMMA International specialize in helping life sciences organizations interpret evolving regulatory expectations, design compliant stability programs, and ensure that product development strategies align with both scientific and regulatory standards. In a landscape where regulatory harmonization and scientific innovation intersect, this type of support can make the difference between delays and successful market entry.
For more information on how EMMA International can assist, visit www.emmainternational.com. Contact EMMA International at (248) 987-4497 or by email at info@emmainternational.com to learn more.
References
Regulatory Affairs Professionals Society. (2025, August 26). Industry wants clarity on scope of ICH stability testing guideline, timing of studies. Retrieved from https://www.raps.org
